Entero Therapeutics, INC 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
GridAI Technologies Corp. reports a net loss of $3.44 million for Q1 2026, with revenue generated from its new AI energy segment.
Entero Therapeutics reported significantly reduced net losses and increased cash, driven by lower operating expenses and a strategic acquisition of AI-driven energy platform Grid AI, while facing ongoing Nasdaq listing compliance challenges and divesting its IMGX subsidiary.
Entero Therapeutics reported significantly reduced net losses and improved cash burn in Q2 2025, but faces substantial doubt about its ability to continue as a going concern amidst critically low cash reserves and ongoing Nasdaq compliance issues.
Entero Therapeutics reports a net loss for Q1 2025 while navigating strategic changes, including a rescission agreement for the ImmunogenX merger and ongoing efforts to address Nasdaq listing requirements.
10-Q: Entero Therapeutics Reports Q3 2024 Results, Faces Going Concern Uncertainty Amid Strategic Review
Entero Therapeutics reports a net loss of $2.6 million for Q3 2024 and is exploring strategic alternatives due to substantial doubt about its ability to continue as a going concern.
Entero Therapeutics' Q2 2024 report reveals a net loss of $3.2 million, a strategic shift involving the disposal of ImmunogenX assets, and substantial doubt about the company's ability to continue as a going concern.
First Wave BioPharma's first quarter of 2024 saw a significant net income of $5.6 million, driven by a tax benefit related to the ImmunogenX acquisition, despite ongoing operating losses.